Aleksander Krag

发表

Diagnostic challenges in patients with alcohol-related liver disease.

Sebastian Mueller, Tania Roskams, Massimo Pinzani, 2022, Zeitschrift fur Gastroenterologie.

Pioneering the path to NASH biomarker approval

M. Rinella, Aleksander Krag, 2023, Nature Medicine.

Review article: the efficacy of biomarkers in chronic fibroproliferative diseases – early diagnosis and prognosis, with liver fibrosis as an exemplar

D. Leeming, J. Sand, P. Christensen, 2014, Alimentary pharmacology & therapeutics.

How to increase value and reduce waste in research: initial experiences of applying Lean thinking and visual management in research leadership

T. Masud, T. Ellingsen, A. Lassen, 2022, BMJ Open.

Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis

W. Laleman, M. Morales-Ruiz, P. Caraceni, 2023, Gut.

Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases.

Schalk van der Merwe, Aleksander Krag, Susana G Rodrigues, 2024, Seminars in immunology.

Review: Opportunities and barriers for omics-based biomarker discovery in steatotic liver diseases.

T. Suvitaival, J. Matthijnssens, M. Israelsen, 2024, Journal of hepatology.

APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure.

S. Sarin, R. Maiwall, S. Tan, 2024, Hepatology international.

AGILE SCORES IN MASLD AND ALD: EXTERNAL VALIDATION AND THEIR UTILITY IN CLINICAL ALGORITHMS.

V. de Lédinghen, M. Thiele, O. Elshaarawy, 2024, Journal of Hepatology.

Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections—Results from the ICA “Global Study” (EABCIR-Global Study)

S. Sarin, L. Lesmana, R. Maiwall, 2023, Hepatology.

Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.

P. Olinga, B. Blagoev, S. Detlefsen, 2023, Journal of hepatology.